Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
Becton Dickinson out for blood with new partnership
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
The extremes converge in big medtech’s hiring practices
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
FDA adcom to pronounce on paclitaxel-coated devices
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
ESC 2018 preview – A possible boost for Abbott, and balloons go up against stents
In a quiet year for medical devices a couple of studies are still worth watching.
Medtechs prioritise efficiency when it comes to hiring
Big cap medtech is hiring, largely thanks to organic growth.
